17952-80-6

Usage

Heterocyclic compound

1H-Pyrido[3,4-b]indole, 6-fluoro-2,3,4,9-tetrahydro belongs to the class of heterocyclic compounds, which are organic compounds containing a ring structure with at least one atom not belonging to the carbon family.

Derivative of pyridoindole

1H-Pyrido[3,4-b]indole, 6-fluoro-2,3,4,9-tetrahydro- is a derivative of pyridoindole, a tricyclic aromatic system consisting of a six-membered pyridine ring fused to a five-membered indole ring.

Fluorine atom at the sixth position

The presence of a fluorine atom at the sixth position of the compound may influence its chemical and biological properties, such as increasing its lipophilicity and metabolic stability.

Tetrahydro group

The presence of a tetrahydro group at positions 2, 3, 4, and 9 of the compound may contribute to its unique properties, such as increased solubility in water and increased molecular weight.

Potential biological activities

1H-Pyrido[3,4-b]indole, 6-fluoro-2,3,4,9-tetrahydro may have potential biological activities due to its unique structure and the presence of functional groups that can interact with biological targets.

Applications in medicinal chemistry

1H-Pyrido[3,4-b]indole, 6-fluoro-2,3,4,9-tetrahydro- may have applications in medicinal chemistry due to its diverse structure and potential pharmacological effects, such as serving as a lead compound for drug discovery or as a building block in the synthesis of more complex molecules.

Further research needed

Further research and studies are needed to fully understand the chemical and biological properties of 1H-Pyrido[3,4-b]indole, 6-fluoro-2,3,4,9-tetrahydro, including its potential applications in drug discovery and development.

Upstream product

• 778-73-4 6-fluoro-2,3,4,9-tetrahydro-β-carbolin-1-one 
• 823-85-8 4-fluorophenyhydrazine hydrochloride 
• 98977-36-7 3-oxo-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1373764-87-4 6-fluoro-N-phenylacetyl-1,3,4,9-tetrahydro-β-carboline 

Relevant academic research and scientific papers

Aromatic heterocyclic derivative and application thereof in medicine

The invention provides aromatic heterocyclic derivatives or stereoisomers, tautomers, nitrogen oxides, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, which are used for treating Alzheimer's disease. The invention also discloses pharmaceutical compositions containing the compounds and a method for treating Alzheimer's disease by using the compounds or the pharmaceutical compositions provided by the invention.

TETRAHYDROBENZOFURO[2,3-C]PYRIDINE AND BETA-CARBOLINE COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES

The present invention relates to novel compounds of formula (I) that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

Synthesis and biological evaluation of novel tetrahydro-β-carboline derivatives as antitumor growth and metastasis agents through inhibiting the transforming growth factor-β signaling pathway

The transforming growth factor beta (TGFβ) signaling cascade is considered as one of the pivotal oncogenic pathways in most advanced cancers. Inhibition of the TGFβ signaling pathway by specific antagonists, neutralizing antibodies, or small molecules is considered as an effective strategy for the treatment of tumor growth and metastasis. Here we demonstrated the identification of a series of tetrahydro-β-carboline derivatives from virtual screening which potentially inhibit the TGFβ signaling pathway. Optimization of the initial hit compound 2-benzoyl-1,3,4,9-tetrahydro-β- carboline (8a) through substitution at different positions to define the structure-activity relationship resulted in the discovery of potent inhibitors of the TGFβ signaling pathway. Among them, compound 8d, one of the tested compounds, not only showed potent inhibition of lung cancer cell proliferation and migration in vitro but also strongly suppressed growth of lung cancer and breast cancer in vivo.

INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF

The present invention can provide a cancer treatment drug containing, as an active ingredient, a substance selected from the group consisting of an indazole compound of the following formula (I), a pharmaceutically acceptable salt, a hydrate, a water adduct and a solvate: